Kevin E. Noonan

home / authors / kevin-e-noonan-0

Kevin E. Noonan, PhD, is a partner at McDonnell Boehnen Hulbert & Berghoff LLP.

Articles

Protecting Intellectual Property for COVID-19 Innovations

Kevin E. Noonan

November 6th 2020

Opposition to IP protection for COVID-19 vaccines, therapies, tests and other technologies may only prevent eradication and treatment of the disease.

Biosimilar Names Prove Difficult to Define

Biosimilar Names Prove Difficult to Define

Kevin E. Noonan

A controversial naming convention attempts to explain important distinctions between biologic drugs and their biosimilar counterparts.

Latest Updated Articles

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

Published: September 11th 2024 | Updated: September 18th 2024

CPHI Pharma Award Finalists Announced for 2024

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Published: March 27th 2024 | Updated: June 28th 2024

AbbVie Acquires Landos Biopharma and Gets Full FDA Nod for ADC Product

Published: December 9th 2024 | Updated: December 22nd 2024

Recap Key Industry Trends for Viral Clearance and NGS

Shining Pro - Stock.Adobe.com

Published: December 7th 2024 | Updated: December 22nd 2024

Enhancing Quality Through Training

Published: July 20th 2020 | Updated: December 22nd 2024

Contact BioPharm International Editors

Published: July 19th 2020 | Updated: December 22nd 2024

Editorial Information: BioPharm International Submission Guidelines and Editorial Calendars

Editorial Information

Do Not Sell My Personal Information

Terms and Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.